NCT06181136View on ClinicalTrials.gov

Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 7, 2023

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Mucopolysaccharidosis Type IIIA
Interventions
DRUG

DNL126

intravenous repeating dose

Trial Locations (4)

27514

University of North Carolina at Chapel Hill, Chapel Hill

52242

University of Iowa Stead Family Children's Hospital, Iowa City

77030

Baylor College of Medicine and Texas Children's Hospital, Houston

94609

UCSF Benioff Children's Hospital Oakland, Oakland

Sponsors
All Listed Sponsors
lead

Denali Therapeutics Inc.

INDUSTRY

NCT06181136 - Study of DNL126 in Pediatric Participants With Mucopolysaccharidosis Type IIIA (Sanfilippo Syndrome Type A) | Biotech Hunter | Biotech Hunter